595 related articles for article (PubMed ID: 8628494)
1. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
[TBL] [Abstract][Full Text] [Related]
2. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
[TBL] [Abstract][Full Text] [Related]
3. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
[TBL] [Abstract][Full Text] [Related]
4. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study.
Nimura T; Yamaguchi K; Ando T; Shibuya S; Oikawa T; Nakagawa A; Shirane R; Itoh M; Tominaga T
J Neurosurg; 2005 Dec; 103(6):968-73. PubMed ID: 16381182
[TBL] [Abstract][Full Text] [Related]
5. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
[TBL] [Abstract][Full Text] [Related]
6. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
[TBL] [Abstract][Full Text] [Related]
7. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors.
Antonini A; Schwarz J; Oertel WH; Beer HF; Madeja UD; Leenders KL
Neurology; 1994 Jul; 44(7):1325-9. PubMed ID: 8035939
[TBL] [Abstract][Full Text] [Related]
8. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.
Rinne JO; Laihinen A; Ruottinen H; Ruotsalainen U; Någren K; Lehikoinen P; Oikonen V; Rinne UK
J Neurol Sci; 1995 Oct; 132(2):156-61. PubMed ID: 8543941
[TBL] [Abstract][Full Text] [Related]
9. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study.
Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Sakamoto M
Ann Neurol; 1999 Nov; 46(5):723-31. PubMed ID: 10553989
[TBL] [Abstract][Full Text] [Related]
10. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.
Politis M; Wu K; Loane C; Brooks DJ; Kiferle L; Turkheimer FE; Bain P; Molloy S; Piccini P
J Clin Invest; 2014 Mar; 124(3):1340-9. PubMed ID: 24531549
[TBL] [Abstract][Full Text] [Related]
11. Chronic exposure to dopamine agonists affects the integrity of striatal D
Politis M; Wilson H; Wu K; Brooks DJ; Piccini P
Neuroimage Clin; 2017; 16():455-460. PubMed ID: 28879087
[TBL] [Abstract][Full Text] [Related]
12. D2 receptor binding in dopa-responsive dystonia.
Künig G; Leenders KL; Antonini A; Vontobel P; Weindl A; Meinck HM
Ann Neurol; 1998 Nov; 44(5):758-62. PubMed ID: 9818931
[TBL] [Abstract][Full Text] [Related]
13. Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status.
Sawle GV; Playford ED; Brooks DJ; Quinn N; Frackowiak RS
Brain; 1993 Aug; 116 ( Pt 4)():853-67. PubMed ID: 8353712
[TBL] [Abstract][Full Text] [Related]
14. Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET.
Linazasoro G; Obeso JA; Gómez JC; Martínez M; Antonini A; Leenders KL
Clin Neuropharmacol; 1999; 22(5):277-80. PubMed ID: 10516878
[TBL] [Abstract][Full Text] [Related]
15. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; Ribeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ;
Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone.
Kaasinen V; Ruottinen HM; Någren K; Lehikoinen P; Oikonen V; Rinne JO
J Nucl Med; 2000 Jan; 41(1):65-70. PubMed ID: 10647606
[TBL] [Abstract][Full Text] [Related]
17. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease.
Antonini A; Leenders KL; Vontobel P; Maguire RP; Missimer J; Psylla M; Günther I
Brain; 1997 Dec; 120 ( Pt 12)():2187-95. PubMed ID: 9448574
[TBL] [Abstract][Full Text] [Related]
18. Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[18F]levodopa positron emission tomography in patients with Parkinson's disease.
Dietz M; Harder S; Graff J; Künig G; Vontobel P; Leenders KL; Baas H
Clin Pharmacol Ther; 2001 Jul; 70(1):33-41. PubMed ID: 11452242
[TBL] [Abstract][Full Text] [Related]
19. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study.
Pavese N; Evans AH; Tai YF; Hotton G; Brooks DJ; Lees AJ; Piccini P
Neurology; 2006 Nov; 67(9):1612-7. PubMed ID: 17101892
[TBL] [Abstract][Full Text] [Related]
20. Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study.
Goerendt IK; Messa C; Lawrence AD; Grasby PM; Piccini P; Brooks DJ;
Brain; 2003 Feb; 126(Pt 2):312-25. PubMed ID: 12538400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]